Mary Ann Liebert: Establishing Time-in-Range as Viable Marker of Glycemic Control
January 09, 2025
January 09, 2025
NEW ROCHELLE, New York, Jan. 9 (TNSres) -- Mary Ann Liebert Inc. issued the following news release:
A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) applied virtual continuous glucose monitoring (CGM) to the data of the landmark Diabetes Control and Complications Trial (DCCT), and showed that 14-day CGM metrics predicted microvascular diabetes complications similarly to glycated hemoglobin. Click here (https://www.liebertpub.com/doi/10.1089/dia.2 . . .
A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) applied virtual continuous glucose monitoring (CGM) to the data of the landmark Diabetes Control and Complications Trial (DCCT), and showed that 14-day CGM metrics predicted microvascular diabetes complications similarly to glycated hemoglobin. Click here (https://www.liebertpub.com/doi/10.1089/dia.2 . . .